ArticleJHEP reports : innovation in hepatology2026
Atezolizumab-bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial.
Yasuto Takeuchi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.